Parkinson
Conditions
Keywords
Parkinson disease, Levodopa induce dyskinesia
Brief summary
Parkinson's disease (PD) is one of the most common neurodegenerative diseases, with a higher prevalence in the elderly. Levodopa induced dyskinesias (LID) are a major motor complications that impair quality of life for patients with PD. The mechanisms of these dyskinesias remain unclear, but several hypotheses have been put forward: non continuous, pulsatile stimulation of dopaminergic receptors, or alterations of other neurotransmitters within the motor striatum such as glutamate and serotonin. Few strategies are now available to treat severe LID: * Medications: reduction of dopaminergic treatment, addition of amantadine, * Functional neurosurgery. The purpose of this study is to investigate the efficacy of buspirone in PD patients suffering from dyskinesias. The role of serotonin in the occurrence of LID was recently demonstrated in transplant PD patients and a test double-blind, single dose was achieved. Following administration of 10 mg oral buspirone, a 5HT1A agonist, LID were clearly improved. A antidyskinetic effect of buspirone had already been reported in 1991 and 1994, but identification of buspirone as a serotonin receptor agonist has been reported more recently. This trial is aimed at (1) validate the serotoninergic hypothesis of hyperkinetic levodopa induced dyskinesias (LID) in Pakinson's disease patients, (2) evaluate, in a phase 3 trial, the motor efficacy of buspirone to improve LID vs placebo, (3) look at a possible dose/effect relationship and (4) check the hypothesis of a better therapeutic ratio using the association of buspirone and amantadine instead than a single drug.
Interventions
DRUGBuspirone
Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
DRUGPlacebo
Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* The subject is an out-patient between 35 year and 80 years of age * Diagnosis of idiopathic Parkinson's disease according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria * Dyskinesias are present more than 25% of the waking day according to item 4-1 of MDS-UPDRS * Dyskinesias are at least moderately disabling item 4-2 of MDS-UPDRS replaced by Dyskinesias are at least slightly disabling item 4-2 of MDS-UPDRS (amendment n°2) * The subject is able to identify dyskinesia, ON and OFF, and apply to his/her own state * Stable dose of anti-Parkinsonian drugs for at least 4 weeks up to the screening * The subject is considered as being optimally treated at the time of inclusion * Written and signed informed consent to participate in the study * Maximal Hoehn and Yahr staging : III in ON phases, IV in OFF * Active affiliation to social security * Menopausal or under contraception for woman
Exclusion criteria
* Female subjects : pregnant or lactating * Atypical parkinsonian syndrome * Weight less than 40 Kgs * Mini-Mental State Examination (MMSE) less than 24 * The subject is participating in another clinical study within the past 12 weeks * Planned participation in another therapeutic clinical study * Previous treatment with buspirone, less than 6 months before Week 0 * Known allergy to buspirone * Known lactose intolerance * Clinically significant illness that might interfere with the study * Dementia or other psychiatric illness * Drug or alcohol abuse replaced by Substance use disorder (alcohol i.e. \> 3 drinks per day for men and \> 2 drinks per day for women,drug, medicinal product) (amendment n°1) * Legal incapacity or limited legal capacity * Deep brain stimulation performed less than 12 months before protocol initiation, or unstable parameters of stimulation 4 weeks before week 0 * Severe renal and / or hepatic impairment * History of seizures or epilepsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Between-group comparison of changes in UDysRS scores | Between baseline and week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Comparison, in both groups of patients of Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part 3-4 (efficacy) | At week 0,Week2, Week4, Week12, Week13 |
| Comparison, in both groups of patients of MDS-UPDRS part 1-2 (quality of life) | At week Week-2, Week0, Week2, Week4, Week12, Week13 |
| Comparison, in both groups of patients of PDQ-39 (quality of life) | At week 0 and week 12 |
| Comparison, in both groups of patients of side effects (tolerance) | At week Week-2, Week0, Week2, Week4, Week12, Week13 |
| Maximum dose accepted by patients (tolerance) | At week Week-2, Week0, Week2, Week4, Week12, Week13 |
Countries
France
Outcome results
None listed